<DOC>
	<DOCNO>NCT01724099</DOCNO>
	<brief_summary>The hypothesis study obese patient Euiiyin-tang 12 week show superior reduction compare take placebo .</brief_summary>
	<brief_title>Evaluating Safety Efficacy Euiiyin-tang Obesity</brief_title>
	<detailed_description>This study two arm , Euiiyin-tang placebo group . Inclusion 80 patient arm . They screen first visit . At baseline , second visit , evaluate outcomes include weight , waist circumference , lipid profile ( total cholesterol , triglyceride ) , CRP ( C-reactive protein ) , visceral fat area subcutaneous fat area use abdominal compute tomography ( CT ) , questionnaires QoL ( Quality Life ) eat attitude , etc . The Euiiyin-tang provide patient baseline , contain 4 week serve . After 4 week , visit 3 , evaluation procedure repeat except lipid profile , CRP , abdominal CT. Another Euiiyin-tang 4 week give patient . The visit 4 , 4 week visit 3 , procedure repeat . The visit 5 , 12 week baseline , patient evaluate include weight , waist circumference , lipid profile , CRP , visceral fat area subcutaneous fat area use abdominal compute tomography , questionnaires QoL eat attitude , etc .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<criteria>1 . Women age 1865 year old 2 . Patients apply one following 2.1 . BMI 30kg/m2 2.2 . BMI 2729.9kg/m2 hypertension proper treatment blood pressure control ( SBP ≤ 145mmHg , DBP ≤ 95mmHg ) 2.3 . BMI 2729.9kg/m2 noninsulindependent diabetes mellitus fast blood glucose &lt; 7.8mmol/L ( 140mg/dL ) 2.4 . BMI 2729.9kg/m2 hyperlipidemia proper treatment 2.5 . BMI 2739.9kg/m2 Total cholesterol 236mg/dL Triglyceride 150mg/dL screen 3 . Agreed lowcalorie diet trial 4 . Written inform consent trial 1 . Endocrine disease hypothyroidism , Cushing 's syndrome , etc . 2 . Heart disease ( heart failure , angina pectoris , myocardial infarction ) 3 . Uncontrolled hypertension ( SBP &gt; 145 mmHg DBP &gt; 95 mmHg ) 4 . Malignant tumour lung disease 5 . Cholelithiasis 6 . Severe renal disability ( SCr &gt; 2.0 mg/dL ) 7 . Severe liver disability ( 2.5 fold normal high range value Alanine Aminotransferase [ ALT ] , Aspartate Aminotransferase [ AST ] , alkaline phosphatase ) 8 . Noninsulindependent diabetes mellitus fast blood sugar 7.8mmol/L ( 140 mg/dL ) 9 . Narrow angle glaucoma 10 . History existence neurological psychological disease ( schizophrenia , epilepsy , alcoholism , drug addiction , anorexia , bulimia , etc . ) 11 . History stroke temporary ischemic cardioplegia 12 . History existence eat disorder anorexia nervosa bulimia nervosa , etc . 13 . Use medication could effect weight within last 3 month ( appetite suppressant , laxative , oral steroid , thyroid hormone , amphetamine , cyproheptadine , phenothiazine medication effect absorption , metabolism , excretion ) 14 . Use βblocker diuretic hypertension medication within last 3 month 15 . Use medication central nervous system central active weight reduction medication 16 . Forbidden treatment ( Insulin , hypoglycemic agent , antidepressant , antiserotonin agent , barbiturate , antipsychotic , medication concern abuse ) 17 . Difficult measure anthropometric dimension anatomical change resection 18 . Surgical history weight reduction ; bariatric surgery , etc . 19 . Unable follow instruction trial judge investigator 20 . Women pregnant , lactating , plan pregnancy woman childbearing age agree proper contraception ( birthcontrol pill , hormone implant , IUD , spermicide , condom , abstinence , etc . ) ( Women childbearing age indicate within 2 year menopause receive hysterectomy , bilateral tubal ligation , bilateral oophorectomy , etc . ) 21 . Use investigational product within last 1 month 22 . Reduction 10 % previous weight within 6 month 23 . Decided stop smoking within last 3 month ; however , keep irregular smoking habit</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Herbal product</keyword>
	<keyword>Korean Medicine</keyword>
</DOC>